Crystalys Therapeutics raised an additional $130 million in a Series B round to advance its gout candidate dotinurad through Phase 3 and prepare for potential commercialization. The drug is already approved in Japan and China, positioning Crystalys for a push into the US and European markets as it scales clinical and manufacturing readiness. The financing underscores sustained investor support for Asia-origin medicines pursuing global expansion.